Astrana Health (ASTH) vs Exponent (EXPO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Astrana Health (ASTH) has outperformed Exponent (EXPO) over the past year, gaining 16.7% versus a gain of 4.8%. Over five years, EXPO leads with a -37.1% price change compared with -49.8% for ASTH. Exponent is the larger company by market cap ($3.32 billion vs $1.78 billion), about 1.9 times the size.
On valuation, Astrana Health trades at a lower forward P/E (9.9x vs 25.7x for Exponent). Exponent pays a dividend yielding 1.75%, while Astrana Health does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASTH | EXPO |
|---|---|---|
| Share price | $35.87 | $69.78 |
| Market cap | $1.78B | $3.32B |
| 1-day change | -3.42% | +1.20% |
| YTD return | +44.58% | +0.46% |
| 1-year return | +16.73% | +4.77% |
| 5-year return | -49.83% | -37.09% |
| P/E ratio (TTM) | 43.22 | 31.29 |
| Forward P/E | 9.86 | 25.65 |
| EPS (TTM) | $0.83 | $2.23 |
| Dividend yield | 0.00% | 1.75% |
| Annual dividend | $0.00 | $1.22 |
| Revenue (latest FY) | — | $582.01M |
| Revenue growth (YoY) | — | +4.21% |
| Net income (latest FY) | — | $106.01M |
| Operating margin | — | 20.58% |
| Net margin | — | 18.21% |
| 52-week high | $51.60 | $81.95 |
| 52-week low | $18.08 | $51.91 |
| Distance from 52-week high | -30.48% | -14.85% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +44.05% | +20.38% |
| Average volume | 462.64K | 510.85K |
| Shares outstanding | 49.60M | 47.55M |
| Employees | 3,000 | 1,012 |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Industry | Professional Services | Professional Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASTH has outperformed EXPO by 12.0 percentage points over the past year.
- Astrana Health trades at a higher earnings multiple (43.2x vs 31.3x trailing P/E).
- Exponent offers a meaningfully higher dividend yield (1.75% vs 0.00%).
About Astrana Health
ASTH stock →Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.
Consumer Discretionary · Professional Services · 3,000 employees
About Exponent
EXPO stock →Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health.
Consumer Discretionary · Professional Services · 1,012 employees
ASTH vs EXPO FAQ
Which is bigger, Astrana Health or Exponent?
Exponent (EXPO) is larger, with a market capitalization of $3.32B compared with $1.78B for Astrana Health (ASTH).
Which stock has performed better over the past year, ASTH or EXPO?
ASTH returned +16.73% over the past 12 months, compared with +4.77% for EXPO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASTH or EXPO?
EXPO has the lower trailing P/E at 31.3, versus 43.2 for ASTH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Astrana Health or Exponent?
Exponent pays a dividend yielding 1.75%, while Astrana Health does not currently pay a regular dividend.
Are Astrana Health and Exponent in the same industry?
Yes. Both are classified in the Professional Services industry within the Consumer Discretionary sector.